FERRY3

Summary

FERRY3 (FERRY endosomal RAB5 effector complex subunit 3, HGNC:1184) is a protein-coding gene on chromosome 12p13.32, encoding Ferry endosomal RAB5 effector complex subunit 3 (Q9NQ89). Component of the FERRY complex (Five-subunit Endosomal Rab5 and RNA/ribosome intermediary).

This gene is highly conserved from nematodes to humans. In rat, the orthologous gene encodes a cytoplasmic protein that is involved in mast cell degranulation. The human gene has been implicated in autosomal recessive intellectual disability.

Source: NCBI Gene 57102 — RefSeq curated summary.

At a glance

• Gene–disease (curated): intellectual disability, autosomal recessive 66 (Strong, GenCC)
• GWAS associations: 5
• Clinical variants (ClinVar): 59 total — 7 pathogenic, 14 likely-pathogenic
• Phenotypes (HPO): 14
• MANE Select transcript: NM_020374

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:1184
Approved symbol	FERRY3
Name	FERRY endosomal RAB5 effector complex subunit 3
Location	12p13.32
Locus type	gene with protein product
Status	Approved
Aliases	Fy-3
Ensembl gene	ENSG00000047621
Ensembl biotype	protein_coding
OMIM	616082
Entrez	57102

Gene structure

Transcript identifiers

Ensembl transcripts: 11 — 6 protein_coding, 2 retained_intron, 2 nonsense_mediated_decay, 1 protein_coding_CDS_not_defined

ENST00000261250, ENST00000509318, ENST00000535030, ENST00000535887, ENST00000541014, ENST00000542080, ENST00000544258, ENST00000544697, ENST00000545746, ENST00000908046, ENST00000908047

RefSeq mRNA: 7 — MANE Select: NM_020374 NM_001304811, NM_001346153, NM_001346155, NM_001346156, NM_001346157, NM_001352962, NM_020374

CCDS: CCDS8528

Canonical transcript exons

ENST00000261250 — 14 exons

Exon	Start	End
ENSE00000713973	4517061	4517189
ENSE00000714024	4518774	4518880
ENSE00000714057	4525254	4525375
ENSE00001214020	4487735	4489899
ENSE00001378522	4538409	4538469
ENSE00003504500	4525484	4525583
ENSE00003517254	4500138	4500340
ENSE00003524752	4536017	4536219
ENSE00003568570	4491177	4491234
ENSE00003600517	4518058	4518255
ENSE00003607410	4534157	4534302
ENSE00003610732	4505306	4505380
ENSE00003676081	4490522	4490589
ENSE00003691502	4529869	4530050

Expression profiles

Bgee: expression breadth ubiquitous, 280 present calls, max score 94.40.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 14.9189 / max 373.1940, expressed in 1751 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
129020	14.9189	1751

Top tissues by expression

290 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
tendon of biceps brachii	UBERON:0008188	94.40	gold quality
buccal mucosa cell	CL:0002336	92.47	gold quality
Brodmann (1909) area 23	UBERON:0013554	90.96	gold quality
middle temporal gyrus	UBERON:0002771	90.46	gold quality
tendon	UBERON:0000043	89.03	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	88.69	gold quality
amniotic fluid	UBERON:0000173	88.49	gold quality
cortical plate	UBERON:0005343	87.81	gold quality
visceral pleura	UBERON:0002401	87.29	gold quality
germinal epithelium of ovary	UBERON:0001304	87.01	gold quality
epithelium of nasopharynx	UBERON:0001951	86.87	gold quality
calcaneal tendon	UBERON:0003701	86.51	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	86.43	gold quality
pons	UBERON:0000988	86.30	gold quality
dorsal root ganglion	UBERON:0000044	86.16	gold quality
tibia	UBERON:0000979	86.01	gold quality
pleura	UBERON:0000977	85.81	gold quality
secondary oocyte	CL:0000655	85.73	gold quality
parietal pleura	UBERON:0002400	85.42	gold quality
skeletal muscle tissue of rectus abdominis	UBERON:0004511	85.28	gold quality
corpus callosum	UBERON:0002336	85.25	gold quality
sperm	CL:0000019	84.88	gold quality
primary visual cortex	UBERON:0002436	84.77	gold quality
medial globus pallidus	UBERON:0002477	84.76	gold quality
esophagus squamous epithelium	UBERON:0006920	84.69	gold quality
trigeminal ganglion	UBERON:0001675	84.44	gold quality
occipital lobe	UBERON:0002021	84.42	gold quality
monocyte	CL:0000576	84.39	gold quality
superior surface of tongue	UBERON:0007371	84.36	gold quality
endometrium	UBERON:0001295	84.33	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ENAD-17	yes	68.49
E-ANND-3	no	4.84

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

79 targeting FERRY3, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-513A-5P	100.00	69.77	2465
HSA-MIR-190A-3P	100.00	80.35	5520
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-548AW	99.99	72.57	3559
HSA-MIR-12136	99.98	72.81	5713
HSA-MIR-4482-3P	99.98	72.50	3147
HSA-MIR-3148	99.97	75.06	6478
HSA-MIR-651-3P	99.94	73.48	5177
HSA-MIR-219A-5P	99.91	73.36	735
HSA-MIR-5680	99.91	69.83	3421
HSA-MIR-4782-3P	99.88	73.31	735
HSA-MIR-6766-3P	99.88	73.38	732
HSA-MIR-3140-3P	99.88	68.47	2069
HSA-MIR-182-5P	99.87	74.03	2589
HSA-MIR-6124	99.87	69.78	3551
HSA-MIR-4760-5P	99.80	69.88	1619
HSA-MIR-6885-3P	99.75	70.36	3187
HSA-MIR-148A-3P	99.74	73.77	1700
HSA-MIR-148B-3P	99.74	73.75	1700
HSA-MIR-152-3P	99.74	73.75	1703
HSA-MIR-4306	99.72	70.50	3630
HSA-MIR-7154-5P	99.69	70.52	1900
HSA-MIR-29B-2-5P	99.67	68.98	1726
HSA-MIR-1251-3P	99.64	67.21	1408
HSA-MIR-567	99.63	68.57	1219
HSA-MIR-8061	99.63	69.44	1411
HSA-MIR-1260A	99.61	66.67	1098
HSA-MIR-1260B	99.61	66.67	1098
HSA-MIR-4649-3P	99.56	66.90	1783
HSA-MIR-4276	99.56	67.66	2514

Literature-anchored findings (GeneRIF, showing 3)

• Mass spectrometry analysis identified protein RGD1311164 (C12orf4), with no previously described function. Our data demonstrate that RGD1311164 is a cytoplasmic protein implicated in the early signaling events following FcepsilonRI-induced cell activation (PMID:25122211)
• Results indicate a founder missense variant (p.Leu328Pro) in seven affected individuals from two Finnish consanguineous families and a deletion (p.Gln267fs) in one affected individual from a consanguineous Dutch family in the C12orf4 gene on chromosome 12. (PMID:27311568)
• A novel variant of C12orf4 linked to autosomal recessive intellectual disability type 66 with phenotype expansion. (PMID:34967075)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	FERRY3	ENSDARG00000060987
mus_musculus	D6Wsu163e	ENSMUSG00000030347
rattus_norvegicus	Ferry3	ENSRNOG00000055036
drosophila_melanogaster	CG9986	FBGN0039589
caenorhabditis_elegans		WBGENE00008339

Protein

Protein identifiers

Ferry endosomal RAB5 effector complex subunit 3 — Q9NQ89 (reviewed: Q9NQ89)

All UniProt accessions (5): Q9NQ89, F5GXX6, F5H271, F5H744, H0YGS6

UniProt curated annotations — full annotation on UniProt →

Function. Component of the FERRY complex (Five-subunit Endosomal Rab5 and RNA/ribosome intermediary). The FERRY complex directly interacts with mRNAs and RAB5A, and functions as a RAB5A effector involved in the localization and the distribution of specific mRNAs most likely by mediating their endosomal transport. The complex recruits mRNAs and ribosomes to early endosomes through direct mRNA-interaction. Plays a role in mast cell degranulation.

Subunit / interactions. Component of the FERRY complex composed of five subunits, TBCK, PPP1R21, FERRY3, CRYZL1 and GATD1 with a ratio of 1:2:1:2:4, respectively.

Subcellular location. Cytoplasm. Early endosome.

Disease relevance. Intellectual developmental disorder, autosomal recessive 66 (MRT66) [MIM:618221] A disorder characterized by significantly below average general intellectual functioning associated with impairments in adaptive behavior and manifested during the developmental period. MRT66 patients have intellectual disability, delayed speech development, neuropsychiatric symptoms, and relatively normal life span. The disease is caused by variants affecting the gene represented in this entry.

RefSeq proteins (7): NP_001291740, NP_001333082, NP_001333084, NP_001333085, NP_001333086, NP_001339891, NP_065107* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR019311	Fy-3	Family

Pfam: PF10154

UniProt features (10 total): sequence conflict 6, sequence variant 2, chain 1, region of interest 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9NQ89-F1	84.04	0.56

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 192 (showing top): GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_UP, GOBP_REGULATION_OF_EXOCYTOSIS, IVANOVA_HEMATOPOIESIS_LATE_PROGENITOR, GOBP_VESICLE_MEDIATED_TRANSPORT, CAGCTG_AP4_Q5, GOBP_LEUKOCYTE_MEDIATED_IMMUNITY, GOBP_REGULATION_OF_VESICLE_MEDIATED_TRANSPORT, GOBP_CELL_ACTIVATION_INVOLVED_IN_IMMUNE_RESPONSE, GOBP_MAST_CELL_ACTIVATION, GOBP_EXOCYTOSIS, CATTTCA_MIR203, GOBP_MYELOID_LEUKOCYTE_ACTIVATION, BLALOCK_ALZHEIMERS_DISEASE_UP, TGIF_01, GOBP_SECRETION

GO Biological Process (1): regulation of mast cell degranulation (GO:0043304)

GO Molecular Function (1): protein binding (GO:0005515)

GO Cellular Component (4): cytoplasm (GO:0005737), early endosome (GO:0005769), protein-containing complex (GO:0032991), endosome (GO:0005768)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
regulation of myeloid leukocyte mediated immunity	1
regulation of leukocyte degranulation	1
mast cell degranulation	1
binding	1
intracellular anatomical structure	1
cellular anatomical structure	1
endosome	1
cellular_component	1
endomembrane system	1
cytoplasmic vesicle	1

Protein interactions and networks

STRING

750 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
FERRY3	TBCK	Q8TEA7	715
FERRY3	PPP1R21	Q6ZMI0	566
FERRY3	TMEM106C	Q9BVX2	529
FERRY3	NOAZFP	Q9Y3S2	445
FERRY3	FHIP1B	Q8N612	437
FERRY3	BRD3OS	A0A1B0GUI7	419
FERRY3	C11orf71	Q6IPW1	396
FERRY3	CLHC1	Q8NHS4	393
FERRY3	LRRC9	Q6ZRR7	392
FERRY3	TMEM50A	O95807	380
FERRY3	FAM120AOS	Q5T036	379
FERRY3	WDR93	Q6P2C0	375
FERRY3	BLTP3A	Q6BDS2	371
FERRY3	RMP64	Q6NW34	369
FERRY3	LRP5L	A4QPB2	355

IntAct

32 interactions, top by confidence:

A	B	Type	Score
PPP1R21	FERRY3	psi-mi:“MI:0407”(direct interaction)	0.790
FERRY3	CRYZL1	psi-mi:“MI:0915”(physical association)	0.690
FERRY3	CASP6	psi-mi:“MI:0915”(physical association)	0.560
FERRY3	HMOX2	psi-mi:“MI:0915”(physical association)	0.560
FERRY3	LAMP2	psi-mi:“MI:0915”(physical association)	0.560
FERRY3	SH3GLB1	psi-mi:“MI:0915”(physical association)	0.560
FERRY3	PRPF40A	psi-mi:“MI:0915”(physical association)	0.560
Tbck	FAM20B	psi-mi:“MI:0914”(association)	0.350
Ptpn23	UMAD1	psi-mi:“MI:0914”(association)	0.350
PPP1R21		psi-mi:“MI:0914”(association)	0.350
TCP10L	RNF40	psi-mi:“MI:0914”(association)	0.350
IL6R	MID1	psi-mi:“MI:0914”(association)	0.350
M		psi-mi:“MI:0914”(association)	0.350
RAB5A	CRYZL1	psi-mi:“MI:0914”(association)	0.350
FERRY3	GAPDHS	psi-mi:“MI:0914”(association)	0.350
TRIM63	FERRY3	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (19): C12orf4 (Affinity Capture-MS), C12orf4 (Affinity Capture-MS), C12orf4 (Affinity Capture-MS), C12orf4 (Affinity Capture-MS), C12orf4 (Affinity Capture-MS), C12orf4 (Two-hybrid), C12orf4 (Two-hybrid), C12orf4 (Affinity Capture-RNA), PDDC1 (Affinity Capture-MS), SRC (Affinity Capture-MS), TBCK (Affinity Capture-MS), GAPDHS (Affinity Capture-MS), C12orf4 (Affinity Capture-MS), C12orf4 (Affinity Capture-MS), CRYZL1 (Affinity Capture-MS)

ESM2 similar proteins: A0JMA8, A0JPP5, A1A535, A1A5P5, F1S5L4, O70481, P86790, P86791, P97564, Q008S8, Q0VA04, Q0VD30, Q14D04, Q16K67, Q19317, Q28HU2, Q2KI89, Q3KQ18, Q45GW3, Q4R6I5, Q4S4I5, Q5GJ77, Q5PQS3, Q5R629, Q5R6E9, Q5RD58, Q5SWX8, Q5U245, Q5XIR8, Q5ZKK3, Q5ZLN2, Q61586, Q6NU25, Q6PA97, Q7Z3E5, Q803R2, Q86VS3, Q8C1Y8, Q8CDK3, Q8IWV7

Diamond homologs: D4A770, Q5RD58, Q91YN0, Q9NQ89

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

59 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	7
Likely pathogenic	14
Uncertain significance	15
Likely benign	8
Benign	1

Top pathogenic / likely-pathogenic (21)

Variant ID	HGVS	Classification
1805729	NM_020374.4(FERRY3):c.187G>T (p.Glu63Ter)	Pathogenic
2081241	NM_020374.4(FERRY3):c.484G>T (p.Glu162Ter)	Pathogenic
2197319	NM_020374.4(FERRY3):c.815_818del (p.Glu272fs)	Pathogenic
3254961	NM_020374.4(FERRY3):c.1043_1044del (p.Thr348fs)	Pathogenic
3392491	NM_020374.4(FERRY3):c.499C>T (p.Arg167Ter)	Pathogenic
872305	GRCh37/hg19 12p13.32(chr12:4599065-4645385)x1	Pathogenic
987171	NM_020374.4(FERRY3):c.1132C>T (p.Gln378Ter)	Pathogenic
1708135	NM_020374.4(FERRY3):c.1168_1169delinsC (p.Gly390fs)	Likely pathogenic
1806586	NM_020374.4(FERRY3):c.500_501GA[2] (p.Arg169fs)	Likely pathogenic
2630920	NM_020374.4(FERRY3):c.670C>T (p.Gln224Ter)	Likely pathogenic
3342369	NM_020374.4(FERRY3):c.916C>T (p.Arg306Ter)	Likely pathogenic
3364092	NM_020374.4(FERRY3):c.729-1G>A	Likely pathogenic
3367098	NM_020374.4(FERRY3):c.527_528del (p.Lys176fs)	Likely pathogenic
3393161	NM_020374.4(FERRY3):c.199C>T (p.Gln67Ter)	Likely pathogenic
4081213	NM_020374.4(FERRY3):c.1003C>T (p.Arg335Ter)	Likely pathogenic
4081214	NM_020374.4(FERRY3):c.40_41del (p.Glu14fs)	Likely pathogenic
4081215	NM_020374.4(FERRY3):c.38_41del (p.Arg13fs)	Likely pathogenic
592163	NM_020374.4(FERRY3):c.983T>C (p.Leu328Pro)	Likely pathogenic
931775	NM_020374.4(C12orf4):c.1200_1201insGT (p.Lys401fs)	Likely pathogenic
977084	NM_020374.4(C12orf4):c.799_1034-429delinsTTATGA	Likely pathogenic
977085	NM_020374.4(C12orf4):c.1078C>T (p.Arg360Ter)	Likely pathogenic

SpliceAI

2670 predictions. Top by Δscore:

Variant	Effect	Δscore
12:4489896:TACT:T	acceptor_gain	1.0000
12:4489898:CT:C	acceptor_gain	1.0000
12:4489900:C:CC	acceptor_gain	1.0000
12:4490026:T:C	donor_gain	1.0000
12:4490517:CATA:C	donor_loss	1.0000
12:4490518:ATACC:A	donor_loss	1.0000
12:4490519:TACCT:T	donor_loss	1.0000
12:4490520:A:C	donor_loss	1.0000
12:4490521:C:CA	donor_loss	1.0000
12:4490587:AACCT:A	acceptor_loss	1.0000
12:4490588:ACC:A	acceptor_loss	1.0000
12:4490590:C:CA	acceptor_loss	1.0000
12:4490590:C:CC	acceptor_gain	1.0000
12:4490591:T:A	acceptor_loss	1.0000
12:4491172:CTCA:C	donor_loss	1.0000
12:4491173:TCA:T	donor_loss	1.0000
12:4491174:CA:C	donor_loss	1.0000
12:4491175:A:AC	donor_gain	1.0000
12:4491176:C:A	donor_loss	1.0000
12:4491176:C:CC	donor_gain	1.0000
12:4491230:ATTTC:A	acceptor_gain	1.0000
12:4491231:TTTC:T	acceptor_gain	1.0000
12:4491233:TC:T	acceptor_gain	1.0000
12:4491233:TCCTA:T	acceptor_loss	1.0000
12:4491234:CC:C	acceptor_gain	1.0000
12:4491235:C:CC	acceptor_gain	1.0000
12:4491235:CTAA:C	acceptor_loss	1.0000
12:4491236:T:C	acceptor_loss	1.0000
12:4491242:C:CT	acceptor_gain	1.0000
12:4491243:A:T	acceptor_gain	1.0000

AlphaMissense

3652 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
12:4490589:C:T	G500D	1.000
12:4491177:C:G	G500R	1.000
12:4491178:T:A	K499N	1.000
12:4491178:T:G	K499N	1.000
12:4491179:T:A	K499I	1.000
12:4491189:T:C	K496E	1.000
12:4500217:C:G	R454P	1.000
12:4500224:C:G	G452R	1.000
12:4500224:C:T	G452R	1.000
12:4518255:C:T	G279E	1.000
12:4518787:A:C	F274L	1.000
12:4518787:A:T	F274L	1.000
12:4518789:A:G	F274L	1.000
12:4489846:G:C	F540L	0.999
12:4489846:G:T	F540L	0.999
12:4489847:A:G	F540S	0.999
12:4489848:A:G	F540L	0.999
12:4490535:A:G	F518S	0.999
12:4490577:T:A	E504V	0.999
12:4490578:C:T	E504K	0.999
12:4490585:G:C	F501L	0.999
12:4490585:G:T	F501L	0.999
12:4490587:A:G	F501L	0.999
12:4491177:C:A	G500C	0.999
12:4491180:T:C	K499E	0.999
12:4491180:T:G	K499Q	0.999
12:4491182:A:T	V498D	0.999
12:4491186:A:G	C497R	0.999
12:4491187:C:A	K496N	0.999
12:4491187:C:G	K496N	0.999

dbSNP variants (sampled 300 via entrez): RS1000099084 (12:4523804 C>G,T), RS1000110653 (12:4517707 A>T), RS1000129103 (12:4499610 G>C), RS1000139328 (12:4494666 T>G), RS1000195109 (12:4494355 C>G,T), RS1000347505 (12:4502283 G>A), RS1000362913 (12:4516920 T>C,G), RS1000365855 (12:4487416 A>G), RS1000386806 (12:4538048 G>A), RS1000459628 (12:4496992 T>C), RS1000578776 (12:4495571 G>A,T), RS1000597854 (12:4509051 C>T), RS1000630215 (12:4508896 G>A,C), RS1000734342 (12:4501287 T>A,C), RS1000742810 (12:4511262 G>T)

Disease associations

OMIM: gene MIM:616082 | disease phenotypes: MIM:618221

GenCC curated gene-disease

Disease	Classification	Inheritance
intellectual disability, autosomal recessive 66	Strong	Autosomal recessive

Mondo (4): intellectual disability, autosomal recessive 66 (MONDO:0032605), intellectual disability (MONDO:0001071), attention deficit-hyperactivity disorder (MONDO:0007743), breast ductal adenocarcinoma (MONDO:0005590)

Orphanet (1): NON RARE IN EUROPE: Unexplained intellectual disability (Orphanet:319658)

HPO phenotypes

14 total (14 of 14 shown, HPO-id order):

HPO	Term
HP:0000007	Autosomal recessive inheritance
HP:0000286	Epicanthus
HP:0000718	Aggressive behavior
HP:0000729	Autistic behavior
HP:0000750	Delayed speech and language development
HP:0001249	Intellectual disability
HP:0001252	Hypotonia
HP:0001263	Global developmental delay
HP:0001290	Generalized hypotonia
HP:0001382	Joint hypermobility
HP:0001999	Abnormal facial shape
HP:0002066	Gait ataxia
HP:0007018	Attention deficit hyperactivity disorder
HP:0100962	Excessive shyness

GWAS associations

5 associations (top):

Study	Trait	p-value
GCST008058_7	Estimated glomerular filtration rate	6.000000e-10
GCST008059_238	Estimated glomerular filtration rate	5.000000e-10
GCST009652_20	Serum alkaline phosphatase levels	1.000000e-09
GCST90011900_76	Serum alkaline phosphatase levels	5.000000e-14
GCST90013406_106	Liver enzyme levels (alkaline phosphatase)	4.000000e-36

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0004533	alkaline phosphatase measurement

MeSH disease descriptors (2)

Descriptor	Name	Tree numbers
D018270	Carcinoma, Ductal, Breast	C04.557.470.200.025.232.500; C04.557.470.615.132.500; C04.588.180.390; C17.800.090.500.390
D008607	Intellectual Disability	C10.597.606.360; C23.888.592.604.646; F01.700.687; F03.625.539

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

33 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects expression, increases expression	3
Benzo(a)pyrene	increases expression, decreases expression	2
dicrotophos	decreases expression	1
methylmercuric chloride	decreases expression	1
kojic acid	decreases expression	1
methylparaben	decreases expression	1
sodium arsenite	affects cotreatment, increases abundance, increases expression	1
manganese chloride	affects cotreatment, increases abundance, increases expression	1
ferrous chloride	decreases expression	1
perfluorooctane sulfonic acid	decreases expression	1
ICG 001	increases expression	1
abrine	increases expression	1
jinfukang	decreases expression	1
Sunitinib	decreases expression	1
Vorinostat	increases expression	1
Arsenic	affects cotreatment, increases abundance, increases expression	1
Atrazine	increases expression	1
Cisplatin	increases expression	1
Dinitrochlorobenzene	decreases expression	1
Doxorubicin	decreases expression	1
Estradiol	increases expression	1
Eugenol	decreases expression	1
Manganese	affects cotreatment, increases abundance, increases expression	1
Methyl Methanesulfonate	increases expression	1
Oxazolone	decreases expression	1
Oxygen	decreases expression	1
Tobacco Smoke Pollution	increases expression	1
Urethane	decreases expression	1
Vitamin E	decreases expression	1
Oxyquinoline	decreases expression	1

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT05657860	PHASE4	COMPLETED	Guanfacine Extended Release for the Reduction of Aggression and Self-injurious Behavior Associated With Prader-Willi Syndrome
NCT05744479	PHASE4	RECRUITING	Metformin for Antipsychotic-induced Weight Gain in Adults With Intellectual Disability
NCT06107829	PHASE4	WITHDRAWN	Valbenazine Treatment of Tardive Dyskinesia in Adults With Intellectual/Developmental Disabilities
NCT06997198	PHASE4	NOT_YET_RECRUITING	Deutetrabenazine Treatment for Tardive Dyskinesia in Intellectual/Developmental Disabilities
NCT00152750	PHASE4	UNKNOWN	Study of Clonidine on Sleep Architecture in Children With Tourette’s Syndrome (TS) and Comorbid ADHD
NCT00181571	PHASE4	COMPLETED	A Double-Blind Comparison of Concerta and Placebo in Adults With Attention Deficit Hyperactivity Disorder
NCT00181675	PHASE4	COMPLETED	A Double-Blind Comparison of Galantamine HBr and Placebo in Adults With Attention Deficit Hyperactivity Disorder
NCT00181714	PHASE4	COMPLETED	Prevention of Cigarette Smoking in Attention Deficit Hyperactivity Disorder (ADHD) Youth With Concerta
NCT00181948	PHASE4	COMPLETED	Strattera Treatment in Children With ADHD Who Have Poor Response to Stimulant Therapy
NCT00181987	PHASE4	COMPLETED	Concerta in the Treatment of ADHD in Youth and Adults With Bipolar Disorder
NCT00190736	PHASE4	COMPLETED	Efficacy and Safety of Once-Daily Atomoxetine Hydrochloride in Adults With ADHD Over an Extended Period of Time (6 Months)
NCT00190775	PHASE4	COMPLETED	A Randomized, Double-Blind Comparison of Placebo and Atomoxetine Hydrochloride Given Once a Day in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
NCT00190879	PHASE4	COMPLETED	Placebo-Controlled Study of Atomoxetine Hydrochloride in the Treatment of Adults With ADHD and Comorbid Social Anxiety Disorder
NCT00190957	PHASE4	COMPLETED	Atomoxetine Treatment of Adults With ADHD and Comorbid Alcohol Abuse
NCT00191035	PHASE4	COMPLETED	Maintenance of Benefit With Atomoxetine Hydrochloride in Adolescents With ADHD
NCT00191048	PHASE4	COMPLETED	Treatment With Atomoxetine Hydrochloride in Children and Adolescents With ADHD
NCT00191633	PHASE4	COMPLETED	Study of Atomoxetine in Children With ADHD to Assess Symptomatic and Functional Outcomes
NCT00191906	PHASE4	COMPLETED	Comparison of Atomoxetine and Placebo in Children With Attention-Deficit/Hyperactivity Disorder (ADHD) and/or Reading Disorder (RD)
NCT00216918	PHASE4	COMPLETED	Neuropsychological Functioning in Children With Attention-Deficit/Hyperactivity Disorder.
NCT00221962	PHASE4	COMPLETED	Study of Aripiprazole (Abilify) in Children With ADHD (Attention Deficit Hyperactivity Disorder)
NCT00223561	PHASE4	COMPLETED	Methylphenidate and Driving Ability in Adult Patients With Attention-Deficit Hyperactivity Disorder
NCT00299234	PHASE4	TERMINATED	Atomoxetine for Children With Acquired Attentional Disorders Following Completion of Chemotherapy for ALL
NCT00302406	PHASE4	COMPLETED	Naturalistic Substitution of Concerta in Adult Subject With ADHD Receiving Immediate Release Methylphenidate
NCT00305370	PHASE4	COMPLETED	Aripiprazole Associated With Methylphenidate in Children and Adolescents With Bipolar Disorder and ADHD
NCT00381758	PHASE4	COMPLETED	The COMACS Study: A Comparison of Methylphenidates in an Analog Classroom Setting
NCT00406354	PHASE4	COMPLETED	Comparison of Atomoxetine Versus Placebo in Children and Adolescents With ADHD and Comorbid ODD in Germany
NCT00434213	PHASE4	COMPLETED	Characterization of Dermal Reactions in Pediatric Patients With ADHD Using DAYTRANA
NCT00468143	PHASE4	COMPLETED	A Within-Subject Cross-Over Comparison Between Immediate Release and Extended Release Adderall
NCT00471354	PHASE4	COMPLETED	A Study for Patients With Attention-Deficit/Hyperactivity Disorder Treated With Atomoxetine
NCT00483106	PHASE4	COMPLETED	Clinical and Pharmacogenetic Study of Attention Deficit With Hyperactivity Disorder (ADHD)
NCT00485849	PHASE4	COMPLETED	A Study of Atomoxetine for Attention Deficit and Hyperactive/Impulsive Behaviour Problems in Children With ASD
NCT00485875	PHASE4	COMPLETED	Safety and Efficacy of Switching From a Stimulant Medication to Atomoxetine in Children and Adolescents With ADHD
NCT00486122	PHASE4	COMPLETED	Evaluation of Continuous Symptom Treatment of ADHD
NCT00500071	PHASE4	COMPLETED	Dose-Optimization Study Evaluating the Efficacy, Safety and Tolerability of Vyvanse (Lisdexamfetamine Dimesylate) in Children Aged 6-12 Diagnosed With ADHD
NCT00506727	PHASE4	COMPLETED	Analog Classroom Study Comparison of ADDERALL XR With STRATTERA in Children Aged 6-12 With ADHD
NCT00510276	PHASE4	COMPLETED	Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) With Atomoxetine in Young Adults and Its Effects on Functional Outcomes
NCT00517504	PHASE4	COMPLETED	Methylphenidate Study in Young Children With Developmental Disorders
NCT00517647	PHASE4	COMPLETED	Atomoxetine Pilot Study in Preschool Children With ADHD
NCT00518232	PHASE4	COMPLETED	A Study to Determine Effective and Tolerable Titration Scheme for OROS-Methylphenidate in Children With Attention-deficit Hyperactivity Disorder
NCT00530257	PHASE4	COMPLETED	Study of the Effects of Osmotic-Release Oral System (OROS) Methylphenidate (Concerta) on Attention and Memory